Vascular smooth muscle mineralocorticoid receptor contributes to coronary and left ventricular dysfunction after myocardial infarction

Hypertension

Volumn 67, Issue 4, 2016, Pages 717-723

  Gueret, Alexandre ^a,b,c   Harouki, Najah ^a,b,c   Favre, Julie ^a,b,c   Galmiche, Guillaume ^d   Nicol, Lionel ^a,b,c   Henry, Jean Paul ^a,b,c   Besnier, Marie ^a,b,c   Thuillez, Christian ^a,b,c   Richard, Vincent ^a,b,c   Kolkhof, Peter ^a,b,c,e   Mulder, Paul ^c   Jaisser, Frédéric ^d   Ouvrard Pascaud, Antoine ^a,b,c  

^a INSERM   (France)

^b UNIVERSITY OF ROUEN   (France)

^c UNIVERSITÉ DE ROUEN   (France)

^d CENTRE DE RECHERCHE DES CORDELIERS   (France)

^e BAYER PHARMA AG   (Germany)

Author keywords

coronary vessels; myocardial infarction; receptors, mineralocorticoid

Indexed keywords

ACETYLCHOLINE; ANGIOTENSIN II; FINERENONE; MINERALOCORTICOID RECEPTOR; NITRIC OXIDE; MINERALOCORTICOID ANTAGONIST; NAPHTHYRIDINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY LIGATION; ENDOTHELIAL DYSFUNCTION; HEART INFARCTION; HEART LEFT VENTRICLE COMPLIANCE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE ENDSYSTOLIC VOLUME; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE PERFUSION; HEART OUTPUT; HEART STROKE VOLUME; HEART VENTRICLE COMPLIANCE; MALE; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OXIDATIVE STRESS; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE; VASCULAR SMOOTH MUSCLE CELL; VASODILATATION; ANIMAL; COMPARATIVE STUDY; COMPLICATION; DISEASE COURSE; DISEASE MODEL; DRUG EFFECTS; DRUG THERAPY; ETIOLOGY; HEART FUNCTION TEST; HEART VENTRICLE REMODELING; METABOLISM; MYOCARDIAL INFARCTION; PHYSIOLOGY; PROCEDURES; RANDOMIZATION; REFERENCE VALUE; RISK ASSESSMENT; RISK FACTOR; TRANSGENIC MOUSE; TREATMENT OUTCOME; VASCULAR SMOOTH MUSCLE;

ANIMALS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; HEART FUNCTION TESTS; MAGNETIC RESONANCE IMAGING; MALE; MICE; MICE, TRANSGENIC; MINERALOCORTICOID RECEPTOR ANTAGONISTS; MUSCLE, SMOOTH, VASCULAR; MYOCARDIAL INFARCTION; NAPHTHYRIDINES; NITRIC OXIDE; OXIDATIVE STRESS; RANDOM ALLOCATION; RECEPTORS, MINERALOCORTICOID; REFERENCE VALUES; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 84960805607     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.115.06709     Document Type: Article

References (25)

1. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J., The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999 341 709 717. doi: 10.1056/NEJM199909023411001.
2. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M, Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003 348 1309 1321. doi: 10.1056/NEJMoa030207.
3. Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pocock SJ, Pitt B, EMPHASIS-HF Study Group EMPHASIS-HF Study Group Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011 364 11 21. doi: 10.1056/NEJMoa1009492.
4. Samuel JL, Delcayre C., Heart failure: aldosterone antagonists are underused by clinicians. Nat Rev Cardiol 2010 7 125 127. doi: 10.1038/nrcardio.2009.244.
5. Fagart J, Hillisch A, Huyet J, Bärfacker L, Fay M, Pleiss U, Pook E, Schäfer S, Rafestin-Oblin ME, Kolkhof P., A new mode of mineralocorticoid receptor antagonism by a potent and selective nonsteroidal molecule. J Biol Chem 2010 285 29932 29940. doi: 10.1074/jbc.M110.131342.
6. Fraccarollo D, Berger S, Galuppo P, Kneitz S, Hein L, Schütz G, Frantz S, Ertl G, Bauersachs J., Deletion of cardiomyocyte mineralocorticoid receptor ameliorates adverse remodeling after myocardial infarction. Circulation 2011 123 400 408. doi: 10.1161/CIRCULATIONAHA.110.983023.
7. Lother A, Berger S, Gilsbach R, Rösner S, Ecke A, Barreto F, Bauersachs J, Schütz G, Hein L., Ablation of mineralocorticoid receptors in myocytes but not in fibroblasts preserves cardiac function. Hypertension 2011 57 746 754. doi: 10.1161/HYPERTENSIONAHA.110.163287.
8. McCurley A, Pires PW, Bender SB, Aronovitz M, Zhao MJ, Metzger D, Chambon P, Hill MA, Dorrance AM, Mendelsohn ME, Jaffe IZ., Direct regulation of blood pressure by smooth muscle cell mineralocorticoid receptors. Nat Med 2012 18 1429 1433. doi: 10.1038/nm.2891.
9. Galmiche G, Pizard A, Gueret A, El Moghrabi S, Ouvrard-Pascaud A, Berger S, Challande P, Jaffe IZ, Labat C, Lacolley P, Jaisser F., Smooth muscle cell mineralocorticoid receptors are mandatory for aldosterone-salt to induce vascular stiffness. Hypertension 2014 63 520 526. doi: 10.1161/HYPERTENSIONAHA.113.01967.
10. Sartório CL, Fraccarollo D, Galuppo P, Leutke M, Ertl G, Stefanon I, Bauersachs J., Mineralocorticoid receptor blockade improves vasomotor dysfunction and vascular oxidative stress early after myocardial infarction. Hypertension 2007 50 919 925. doi: 10.1161/HYPERTENSIONAHA.107.093450.
11. Mulder P, Mellin V, Favre J, Vercauteren M, Remy-Jouet I, Monteil C, Richard V, Renet S, Henry JP, Jeng AY, Webb RL, Thuillez C., Aldosterone synthase inhibition improves cardiovascular function and structure in rats with heart failure: a comparison with spironolactone. Eur Heart J 2008 29 2171 2179. doi: 10.1093/eurheartj/ehn277.
12. Bärfacker L, Kuhl A, Hillisch A, Grosser R, Figueroa-Pérez S, Heckroth H, Nitsche A, Ergüden JK, Gielen-Haertwig H, Schlemmer KH, Mittendorf J, Paulsen H, Platzek J, Kolkhof P., Discovery of BAY 94-8862: a nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases. ChemMedChem 2012 7 1385 1403. doi: 10.1002/cmdc.201200081.
13. Kolkhof P, Delbeck M, Kretschmer A, Steinke W, Hartmann E, Bärfacker L, Eitner F, Albrecht-Küpper B, Schäfer S., Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury. J Cardiovasc Pharmacol 2014 64 69 78. doi: 10.1097/FJC.0000000000000091.
14. Lu L, Quinn MT, Sun Y., Oxidative stress in the infarcted heart: role of de novo angiotensin II production. Biochem Biophys Res Commun 2004 325 943 951. doi: 10.1016/j.bbrc.2004.10.106.
15. Rickard AJ, Morgan J, Chrissobolis S, Miller AA, Sobey CG, Young MJ., Endothelial cell mineralocorticoid receptors regulate deoxycorticosterone/salt-mediated cardiac remodeling and vascular reactivity but not blood pressure. Hypertension 2014 63 1033 1040. doi: 10.1161/HYPERTENSIONAHA.113.01803.
16. Calvier L, Miana M, Reboul P, Cachofeiro V, Martinez-Martinez E, de Boer RA, Poirier F, Lacolley P, Zannad F, Rossignol P, López-Andrés N., Galectin-3 mediates aldosterone-induced vascular fibrosis. Arterioscler Thromb Vasc Biol 2013 33 67 75. doi: 10.1161/ATVBAHA.112.300569.
17. Ambroisine ML, Favre J, Oliviero P, Rodriguez C, Gao J, Thuillez C, Samuel JL, Richard V, Delcayre C., Aldosterone-induced coronary dysfunction in transgenic mice involves the calcium-Activated potassium (BKCa) channels of vascular smooth muscle cells. Circulation 2007 116 2435 2443. doi: 10.1161/CIRCULATIONAHA.107.722009.
18. Xu J, Carretero OA, Lin CX, Cavasin MA, Shesely EG, Yang JJ, Reudelhuber TL, Yang XP., Role of cardiac overexpression of ANG II in the regulation of cardiac function and remodeling postmyocardial infarction. Am J Physiol Heart Circ Physiol 2007 293 H1900 H1907. doi: 10.1152/ajpheart.00379.2007.
19. Patten RD, Aronovitz MJ, Einstein M, Lambert M, Pandian NG, Mendelsohn ME, Konstam MA., Effects of angiotensin II receptor blockade versus angiotensin-converting-enzyme inhibition on ventricular remodelling following myocardial infarction in the mouse. Clin Sci (Lond) 2003 104 109 118. doi: 10.1042/CS20020219.
20. Rautureau Y, Paradis P, Schiffrin EL., Cross-Talk between aldosterone and angiotensin signaling in vascular smooth muscle cells. Steroids 2011 76 834 839. doi: 10.1016/j.steroids.2011.02.015.
21. Johar S, Cave AC, Narayanapanicker A, Grieve DJ, Shah AM., Aldosterone mediates angiotensin II-induced interstitial cardiac fibrosis via a Nox2-containing NADPH oxidase. FASEB J 2006 20 1546 1548. doi: 10.1096/fj.05-4642fje
22. Martinez-Lemus LA, Crow T, Davis MJ, Meininger GA., alphavbeta3- And alpha5beta1-integrin blockade inhibits myogenic constriction of skeletal muscle resistance arterioles. Am J Physiol Heart Circ Physiol 2005 289 H322 H329. doi: 10.1152/ajpheart.00923.2003.
23. Marks DS, Gudapati S, Prisant LM, Weir B, diDonato-Gonzalez C, Waller JL, Houghton JL., Mortality in patients with microvascular disease. J Clin Hypertens (Greenwich) 2004 6 304 309
24. Montalescot G, Pitt B, Lopez de Sa E, Hamm CW, Flather M, Verheugt F, Shi H, Turgonyi E, Orri M, Vincent J, Zannad F, REMINDER Investigators; REMINDER Investigators REMINDER Investigators; REMINDER Investigators Early eplerenone treatment in patients with acute ST-elevation myocardial infarction without heart failure: the Randomized Double-Blind Reminder Study. Eur Heart J 2014 35 2295 2302. doi: 10.1093/eurheartj/ehu164.
25. Joffe HV, Kwong RY, Gerhard-Herman MD, Rice C, Feldman K, Adler GK., Beneficial effects of eplerenone versus hydrochlorothiazide on coronary circulatory function in patients with diabetes mellitus. J Clin Endocrinol Metab 2007 92 2552 2558. doi: 10.1210/jc.2007-0393.